Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NorthSea Therapeutics BV

www.northseatherapeutics.com

Latest From NorthSea Therapeutics BV

Venture Funding Deals: Orchard Therapeutics Spreads Its Roots

Rare disease gene therapy play Orchard added new investors in an oversubscribed Series B raising $110m and therapeutic antibody developer Allakos raised $100m in its Series B round, while Obsidian raises $49.5m for next-generation cancer cell therapies in Series A.

StartUps and SMEs Financing
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Hepatic (Liver)
  • Inflammation
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Benelux
          • Netherlands
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • NorthSea Therapeutics BV
  • Senior Management
  • Rob de Ree, CEO
    Mats Blom, CFO
    David A Fraser, PhD, CSO
    Hilde H Steineger, PhD, COO
    Patrick Round, MD, CMO
  • Contact Info
  • NorthSea Therapeutics BV
    Phone: 35 760 65 05
    Gooimeer 2-35
    Naarden, 1411 DC
    Netherlands
Advertisement
Advertisement
UsernamePublicRestriction

Register